2024-05-06 08:46:14
Stallergenes Greer, a biopharmaceutical laboratory specializing in allergen immunotherapy (ITA), announces the results of its real-world study, EfficAPSI, evaluating the effect of its sublingual ITA solutions on the onset and progression of asthma in patients with allergic rhinitis, was published in the journal The Lancet Regional Health-Europe. This article has already been published online (https://doi.org/10.1016/j.lanepe.2024.100915), will soon be available in print.
This real-life longitudinal and retrospective pharmaco-epidemiological study evaluated, over a period of 9 years, more than 440,000 patients: more than 110,000 patients suffering from allergic rhinitis, with or without asthma, treated with Stallergenes Greer sublingual solutions and symptomatic medications; compared with more than 330,000 patients suffering from allergic rhinitis, with or without asthma, treated only with symptomatic drugs.
The main objective of the study was to evaluate the real effect of Stallergenes Greer sublingual solutions in preventing the onset and exacerbation of asthma in patients with allergic rhinitis. The results of the study are consistent across all age categories (from 5 years), allergens and evaluation criteria.
EfficAPSI showed, in patients treated with Stallergenes Greer sublingual solutions and symptomatic medications, compared to patients treated with only symptomatic medications:
- a 36% reduction in the risk of new asthma attacks across the cohort*;
- a 38% reduction in the risk of developing asthma in patients without existing asthma;
- a reduction by one third in the intensification of treatment recommended within the framework of the Global Initiative for Asthma (GINA), in patients suffering from existing asthma, demonstrating the effectiveness of sublingual solutions in preventing asthma exacerbations.
“I am pleased to communicate this large EfficAPSI study to the medical community through its publication in The Lancet Regional Health-Europe. EfficAPSI confirms the role of sublingual solutions in improving asthma management. The results provide important data on the relevance of sublingual solutions as an etiological treatment which allows personalized treatment, adapted to the unique needs of each individual patient, and offers better clinical outcomes,” declares Professor Pascal Demoly, Head of Pulmonary, Allergy and Thoracic Oncology at Montpellier University Hospital (France), President of the French Society of Allergology, and member by the study’s scientific committee.
“It is important to study the effect of allergen immunotherapy on the onset and progression of asthma. Through this real-world EfficAPSI study, Stallergenes Greer is proud to provide scientific evidence and valuable insight into allergy treatment. We remain focused on developing solutions to alter disease progression , driven by robust clinical data, to redefine the management of respiratory diseases and improve the quality of life of people suffering from allergies.” , says Dr. Elena Rizova, Medical Director of Stallergenes Greer.
By demonstrating their benefits with regard to the onset and exacerbation of asthma, Stallergenes Greer’s sublingual solutions confirm their utility in public health. Stallergenes Greer intends to intensify the use of this approach in real life to strengthen the level of evidence for the benefits of its sublingual ITA treatments. Other criteria are currently under review and will be published later.
Source and image: Stallergenes Greer
*combined score
________________________________
1 Demoly P, Molimard M, Bergmann JF, et al. Effect of liquid sublingual immunotherapy on asthma onset and progression in patients with allergic rhinitis: a nationwide population-based study (EfficAPSI study). Lancet Reg Health Eur. 2024.
2 Demoly P, Corren J, Creticos P, et al. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial. J Allergy Clin Immunol. 2021;147(3):1020-1030.e10
3 Bousquet J, Khaltaev N, Cruz A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr;63 Suppl 86:8-160.
4 Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines – 2016 revision. J Allergy Clin Immunol. 2017;140(4):950–8
5 Linneberg A., Henrik Nielsen N., Frolund L, et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Allergy Study in Copenhagen. Allergy. 2002 Nov;57(11):1048-1052.
6 Shin JW, Sue JH, Song TW, et al. Atopy and house dust mite sensitization as risk factors for asthma in children. Yonsei Med J. 2005;46: 629-634.
7 Hankin CS, Cox L, Lang D, et al. Allergen immunotherapy and healthcare cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol. 2010 Jan;104(1):79-85
1714986847
#Stallergenes #Greer #publishes #journal #Lancet #Regional #HealthEurope #large #study #EfficAPSI
